Jaguar Health financials
$6.02−21.82%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $20.3M | $3.2M | $3.1M | $3.0M | $2.2M | $3.5M | $3.1M | $2.7M | $2.4M | $2.3M | $2.8M |
| Gross profit | $194.0K | $19.1M | $1.0M | $2.6M | $2.5M | $1.7M | $3.0M | $2.6M | $2.3M | $1.9M | $1.6M | $2.3M |
| Gross margin | 15.8% | 94.3% | 32.0% | 82.7% | 82.3% | 76.7% | 84.1% | 82.6% | 84.3% | 81.7% | 70.1% | 81.7% |
| Operating income | -$7.6M | $10.2M | -$20.4M | -$7.2M | -$8.0M | -$9.4M | -$8.2M | -$7.3M | -$7.2M | -$8.2M | -$7.6M | -$8.8M |
| Net income | -$12.7M | -$7.0M | -$23.2M | -$9.5M | -$10.4M | -$10.5M | -$9.9M | -$9.9M | -$9.5M | -$9.2M | -$9.2M | -$7.8M |
| Net margin | −1036.8% | −34.6% | −717.2% | −308.2% | −349.3% | −472.6% | −282.7% | −317.1% | −348.8% | −392.4% | −398.7% | −276.5% |
| Diluted EPS | $-235.50 | $-204.00 | $-1567.80 | $-2724.79 | $-5384.10 | $-8766.75 | — | $-11406.82 | $-1154.13 | $-37800.00 | $-68975.54 | $-244059.92 |
| EBITDA | -$7.1M | $10.7M | -$20.0M | -$6.8M | -$7.5M | -$8.9M | -$7.7M | -$6.8M | -$6.8M | -$7.7M | -$7.2M | -$8.3M |
| Operating cash flow | -$5.3M | $8.8M | -$5.5M | -$4.7M | -$6.2M | -$7.3M | -$7.8M | -$6.3M | -$8.2M | -$7.0M | -$7.5M | -$6.8M |
| Free cash flow | -$5.3M | $8.8M | -$5.5M | -$4.7M | -$6.2M | -$7.3M | -$7.8M | -$6.3M | -$8.2M | -$7.0M | -$7.5M | -$6.8M |
| Diluted shares | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | — | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.8M | $7.3M | $968.0K | $3.5M | $2.2M | $5.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $15.6M | $33.2M | $42.5M | $30.8M | $29.3M | $37.1M |
| Total assets | $34.2M | $37.4M | $38.3M | $49.5M | $48.3M | $51.5M |
| Total liabilities | $29.3M | $53.2M | $57.0M | $45.1M | $41.4M | $48.1M |
| Shareholders' equity | $4.9M | -$15.8M | -$18.7M | $4.4M | $6.9M | $830.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology